Five-Year Survival 80 percent for limited disease, 20 percent for extensive disease with bone marrow and central nervous system involvement
Investigational
• Intensified treatment for high-risk patients is being investigated. One strategy is early use of bone marrow
transplantation.
Therapy for Relapsed Disease Secondary chemotherapy and bone marrow transplantation at relapse have some antitumor activity but have most often failed to cure this rapidly fatal condition.
Small Non-Cleaved Cell Lymphoma (Burkitt's/Non-Burkitt's)
Standard Treatment The management of this lymphoma is similar to that of lymphoblastic lymphoma. Multi-agent chemotherapy, based upon high-dose cyclophosphamide , frequently incorporates methotrexate , vincristine , prednisone and doxorubicin together with central nervous system prophylactic therapy.
Patients with extensive disease—usually Stage IV on the basis of bone marrow and especially central nervous system involvement—and a high serum lactate dehydrogenase (LDH) have generally fared poorly with chemotherapy.
More intensive treatment programs used successfully in pediatric cases, with or without bone marrow transplantation, are under investigation.
